Zhejiang Medicine Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	8,919	9,336	7,762	8,073	9,088	7,294
Other Revenue	38.76	38.76	32.11	43.23	41.3	32.53
Revenue	8,958	9,375	7,794	8,116	9,129	7,327
Revenue Growth (YoY)	-0.80%	20.29%	-3.96%	-11.10%	24.60%	4.02%
Cost of Revenue	5,512	5,591	5,392	5,438	5,530	4,410
Gross Profit	3,446	3,785	2,402	2,678	3,599	2,917
Selling, General & Admin	1,458	1,678	1,481	1,312	1,546	1,537
Research & Development	675.7	749.35	860.07	809.28	806.86	546.09
Other Operating Expenses	92.42	96.54	78.43	69.86	75.17	73.04
Operating Expenses	2,232	2,537	2,420	2,188	2,439	2,140
Operating Income	1,214	1,248	-18.15	489.74	1,160	777.42
Interest Expense	-23.39	-26.37	-28.34	-33.11	-39.54	-46.27
Interest & Investment Income	33.61	22.51	16.51	13.18	57.42	139.56
Currency Exchange Gain (Loss)	17.82	17.82	36.59	66.6	-64.31	-38.46
Other Non Operating Income (Expenses)	89.87	3.9	21.09	-36.73	-2.69	-31.87
EBT Excluding Unusual Items	1,332	1,266	27.7	499.67	1,111	800.38
Impairment of Goodwill	-18.68	-18.68	-9.23	-8.12	-	-
Gain (Loss) on Sale of Investments	11.56	-29.6	-28.59	-56.51	51.73	30.48
Gain (Loss) on Sale of Assets	-4.4	-5.21	323.57	-1.37	-7.95	-23.48
Asset Writedown	-62.14	-69.41	-	-	-46.19	-9.85
Other Unusual Items	69.46	69.46	49.82	57.71	44.76	53.45
Pretax Income	1,328	1,212	363.28	491.39	1,154	850.98
Income Tax Expense	199.36	192.03	86.48	128.77	268.97	191.34
Earnings From Continuing Operations	1,128	1,020	276.79	362.61	884.56	659.64
Minority Interest in Earnings	115.58	140.26	152.85	176.96	160.76	57.76
Net Income	1,244	1,161	429.64	539.57	1,045	717.4
Net Income to Common	1,244	1,161	429.64	539.57	1,045	717.4
Net Income Growth	27.21%	170.11%	-20.37%	-48.38%	45.71%	109.29%
Shares Outstanding (Basic)	959	962	955	964	959	957
Shares Outstanding (Diluted)	959	962	955	964	959	957
Shares Change (YoY)	0.97%	0.72%	-0.91%	0.47%	0.26%	0.46%
EPS (Basic)	1.30	1.21	0.45	0.56	1.09	0.75
EPS (Diluted)	1.30	1.21	0.45	0.56	1.09	0.75
EPS Growth	25.99%	168.18%	-19.64%	-48.62%	45.33%	108.33%
Free Cash Flow	1,516	534.15	-162.56	-455.39	197.05	721.37
Free Cash Flow Per Share	1.58	0.56	-0.17	-0.47	0.20	0.75
Dividend Per Share	0.370	0.370	0.150	0.170	0.330	0.230
Dividend Growth	146.67%	146.67%	-11.77%	-48.48%	43.48%	-77.00%
Gross Margin	38.47%	40.37%	30.82%	33.00%	39.43%	39.81%
Operating Margin	13.55%	13.31%	-0.23%	6.03%	12.71%	10.61%
Profit Margin	13.89%	12.38%	5.51%	6.65%	11.45%	9.79%
Free Cash Flow Margin	16.93%	5.70%	-2.09%	-5.61%	2.16%	9.84%
EBITDA	1,818	1,903	706.04	1,171	1,747	1,281
EBITDA Margin	20.30%	20.30%	9.06%	14.42%	19.14%	17.49%
D&A For EBITDA	604.19	655.62	724.19	680.81	586.79	503.81
EBIT	1,214	1,248	-18.15	489.74	1,160	777.42
EBIT Margin	13.55%	13.31%	-0.23%	6.03%	12.71%	10.61%
Effective Tax Rate	15.01%	15.84%	23.81%	26.21%	23.32%	22.48%
Revenue as Reported	8,958	9,375	7,794	8,116	9,129	7,327
Advertising Expenses	-	18.46	21.25	19.59	21.3	20.8

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.